

## AstraZeneca R&D Pipeline: NCEs 3 December 2001

### Cardiovascular

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
Crestor	Statin	Hyperlipidemia	DFL	Filed	Filed
Exanta™(melagatran)	Thrombin inhibitor (s.c)	Prevention of VTE	DFL	3Q 2002	>2004
Exanta™ (H376/95)	Thrombin inhibitor	Prevention of VTE	DFL	3Q 2002	2Q 2003
Exanta™ (H376/95)	Thrombin inhibitor	Prevention of stroke in AF	DFL	2Q 2003	2Q 2003
Exanta™ (H376/95)	Thrombin inhibitor	Treatment of VTE	DFL	1H 2003	2004
Exanta™ (H376/95)	Thrombin inhibitor	Post Acute Coronary Syndrome	CT	>2004	>2004
AZD 6140	P <sub>2</sub> T antagonist	Arterial thrombosis	CT	>2004	>2004
AZ 242	PPAR agonist	Diabetes /Insulin resistance	CT	>2004	>2004
AZD 7545	PDK inhibitor (anti-diabetic)	Diabetes	CT	>2004	>2004
AZD 7009	Atrial Repolarisation Delaying Agent (ARDA)	Atrial Fibrillation	CT	>2004	>2004

### Gastrointestinal

AR-H047108	Reversible acid pump inhibitor	Acid related GI disease	CT	>2004	>2004
AZD 3355 (Reflux inhibitor)	Inhibitor of transient lower esophageal sphincter relaxations (TLESR)	Gastroesophageal reflux disease (GERD)	CT	>2004	>2004
Rofleponide	Oral steroid with topical action	Inflammatory bowel disease	CT	>2004	>2004

### CNS

NXY-059	Free radical trapping agent	Stroke	CT	>2004	>2004
NAD 299	5HT <sub>1A</sub> antagonist	Anxiety/Depression	CT	>2004	>2004
AR-A2	5HT <sub>1β</sub> antagonist	Anxiety/Depression	CT	>2004	>2004
ZD 0947	K <sup>+</sup> channel opener	overactive bladder	CT	>2004	>2004
AZD 5106	NK-2 antagonist	overactive bladder	CT	>2004	>2004

## Oncology

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
Faslodex™	Estrogen Receptor Down regulator	2 <sup>nd</sup> line Advanced breast cancer	DFL	2002	Filed
Faslodex™	Estrogen Receptor Down regulator	1 <sup>st</sup> line Advanced breast cancer	DFL	2002	2002
Iressa™	Signal transduction inhibitor (Epidermal growth factor receptor tyrosine kinase inhibitor)	NSCLC and other solid tumours	DFL	2Q 2002*	4Q 2001*
ZD 9331	Thymidilate synthase inhibitor (iv)	Solid tumours	CT	2004	2004
ZD 9331	Thymidilate synthase inhibitor (oral)	Solid tumours	CT	>2004	>2004
ZD 6126	Vascular targeting agent	Solid tumours	CT	>2004	>2004
AZD 6474	Angiogenesis inhibitor (Vascular endothelial cell growth factor receptor tyrosine kinase inhibitor)	Solid tumours	CT	>2004	>2004
AZD 2171	Angiogenesis inhibitor (Vascular endothelial cell growth factor receptor tyrosine kinase inhibitor)	Solid tumours and haematological malignancies	CT	>2004	>2004
AZD 3409	Farnesyl-transferase inhibitor ( FAR )	Solid tumours	CT	>2004	>2004

\*US filing NSCLC monotherapy 4Q 2001, combination 2Q 2002; EU filing NSCLC monotherapy and combination 2Q 2002

## Respiratory and Inflammation

Rofleponide palmitate	Intranasal steroid	Rhinitis	CT	2004	2004
ZD 4407	5-lipoxygenase inhibitor	COPD	CT	>2004	>2004
ZD 2315	Immuno modulator	Rheumatoid Arthritis	CT	>2004	>2004
AZD 9056	Ion channel blocker	Rheumatoid Arthritis	CT	>2004	>2004
AZD 8309	Chemokine receptor antagonist	Rheumatoid Arthritis	CT	>2004	>2004

## Pain Control

AZD 3582 (NO-naproxen)	Nitric oxide NSAID derivative	Acute /chronic pain	CT	>2004	>2004
AZD 4282 (oral glycine)	NMDA Antagonist	Neuropathic pain	CT	>2004	>2004

## Infection

AZD2563	Oxazolidinone antibiotic	Gram positive infections, including multi-resistant strains	CT	>2004	>2004
---------	--------------------------	---	----	-------	-------

## AstraZeneca R&D Pipeline: Line Extensions

### Cardiovascular

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
Atacand <sup>®</sup>	Angiotensin II antagonist	Hypertension outcomes (SCOPE study)	DFL	3Q 2002	3Q 2002
		CHF outcomes (CHARM study)	DFL	2H 2003	2H 2003
		Diabetic retinopathy	DFL	>2004	>2004

NB. Paediatric programmes ongoing/planned: Atacand<sup>®</sup>, Seloken<sup>®</sup>/Toprol<sup>®</sup>.

### Gastrointestinal

Nexium <sup>®</sup>	Proton pump inhibitor	Multiple indications	DFL	2003*	2003*
---------------------	-----------------------	----------------------	-----	-------	-------

\*Multiple indications from 2003 onwards

### CNS

Seroquel <sup>®</sup>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	Granules	DFL	1H 2003	1H 2003
Seroquel <sup>®</sup>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	Sustained release	DFL	4Q 2002	4Q 2002
Seroquel <sup>®</sup>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	Mania	DFL	1H 2003	2H 2002
Zomig <sup>®</sup>	5-HT <sub>1B/1D</sub> receptor agonist	Adolescents	DFL	2H 2003	2H 2003
Zomig <sup>®</sup>	5-HT <sub>1B/1D</sub> receptor agonist	Nasal spray	DFL	Filed	1Q 2002

### Oncology

Arimidex <sup>®</sup>	Aromatase inhibitor	Adjuvant Breast Cancer	DFL	1Q 2002	1Q 2002
Casodex <sup>®</sup>	Anti-androgen	Early Prostate Cancer	DFL	Filed	4Q 2001
Zoladex <sup>®</sup>	LHRH agonist	Premenopausal Adjuvant Breast Cancer	DFL	Launched	1H 2003

### Respiratory

Symbicort <sup>®</sup> Turbuhaler	Inhaled steroid/long-acting $\beta_2$ agonist	COPD	DFL	1Q 2002	
Symbicort Turbuhaler	Inhaled steroid/long-acting $\beta_2$ agonist	Single therapy for asthma	DFL	2H 2003	
Symbicort <sup>®</sup> pMDI	Inhaled steroid/long-acting $\beta_2$ agonist	Asthma	DFL	2H 2003	2004
Oxis <sup>®</sup> Turbuhaler <sup>®*</sup>	Long-acting $\beta_2$ agonist	COPD	DFL	2Q 2002	
Oxis <sup>®</sup> Turbuhaler <sup>®*</sup>	Long-acting $\beta_2$ agonist	Paediatrics Asthma	DFL	Filed	
Oxis <sup>®</sup> pMDI*	Long-acting $\beta_2$ agonist	Asthma / COPD	DFL	2H 2003	

\* Following a review, Oxis<sup>®</sup> will not be developed for the US market and resources will focus on Symbicort<sup>®</sup> pMDI

### Pain Control

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
Naropin <sup>®</sup>	Sodium channel blocker	Spinal anaesthesia	DFL	Filed	*

\* Naropin will not be filed for spinal anaesthesia in the US

## Infection

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
Merrem <sup>®</sup>	Carbapenem antibiotic	Use in Neutropenics	DFL		2H 2003
Merrem <sup>®</sup>	Carbapenem antibiotic	Skin and soft tissue infections	DFL		1H 2003

## AstraZeneca R&D Pipeline: Discontinued Compounds

### Cardiovascular

Compound	Mechanism
AR-H050642	Atrial Repolarisation Delaying Agent (ARDA) – replaced by AZD 7009
ZD 4927	Factor Xa inhibitor

### Oncology

Compound	Mechanism
ZD 0473*	3 <sup>rd</sup> generation platin (iv)
ZD 0473*	3 <sup>rd</sup> generation platin (oral)

\*Handed back to Anormed 26 Nov 2001

### Respiratory and Inflammation

Compound	Mechanism
AZD 6942 (CCR2b)	Immuno modulator

### Comments

As disclosure of compound information is balanced by the business need to maintain competitive advantage, some compound information has not been disclosed at this time.

Previous pipeline tables have displayed projects in the pre-clinical stage (prior to the selection of a candidate drug). The current table shows compounds in concept testing and development for launch only.

AstraZeneca is using a new terminology for the stage of development;

CT – concept testing, from CD nomination, through to phase I and phase II completion  
DFL – development for launch, phase IIIa and phase IIIb activities conducted prior to filing

Other abbreviations;

CD – Candidate Drug  
MAA - Marketing Authorisation Application (Europe)  
NDA – New Drug Application (USA)